GENEART Announces 1:1 Stock Dividend to Boost the Market Liquidity of
its Stock
- A proposal to issue a stock dividend will be submitted to a vote at
the Shareholders' Meeting on July 24, 2007.
- GENEART plans to double the share capital through a capital stock
increase from company funds in a 1:1 ratio.
- As a result, each shareholder would receive one additional share
for every held share.
- The stock issue does not involve the allocation of new
shareholders' equity.
Regensburg (Germany), June 06, 2007 - To boost the market liquidity
of the company shares the members of the GENEART AG Board of
Directors and the Advisory Board plan to suggest a 1:1 increase in
capital stock from company funds at the Shareholders' Meeting on July
24, 2007. Each GENEART AG shareholder would receive one additional
share for every held company share. The capital increase from company
funds in the proposed amount doubles the company's share capital
without an infusion of new shareholders' equity.
The suggested issuing of one new ordinary share in the name of the
holder for every already held share also doubles the number of
company shares. After the increase in share capital from company
funds, each ordinary share will retain its value of EUR 1.00.
Doubling the share capital and the number of traded ordinary shares
is meant to boost the market liquidity of the GENEART shares and make
them more attractive to a broader circle of investors. Pending the
vote of the Shareholders' Meeting and subject to the prescribed
terms, the new shares are expected to be issued in September. GENEART
will make another announcement close to the issue date.
For further inquiries, please contact:
Bernd Merkl Frank Ostermair
GENEART AG Haubrok Investor Relations GmbH
Josef-Engert-Str. 11 Maximilianstraße 45
D-93053 Regensburg 80538 München
Tel.: +49-(0)941-942 76 - 38 Tel: +49-(0)89-21027-204
Fax: +49-(0)941-942 76 - 75 Fax: +49-(0)89-21027-298
ir@geneart.com f.ostermair@haubrok.de
www.geneart.com
About GENEART AG
Founded in 1999, GENEART today is the globally leading specialists
providing optimized gene solutions to research institutions as well
as the pharma, biotech and chemical industries. GENEART offers
integrated product systems based on gene synthesis for developing
innovative drugs, in particular DNA- and protein-based therapeutics
and vaccines, as well as for identifying improved industrial enzymes.
The service portfolio ranges from the manufacturing of optimized
synthetic genes in accordance with DIN EN ISO 9001:2000 and the
generation of gene libraries in combinatorial biology, to the
production and development of DNA-based drugs. GENEART, currently a
team of more than 120 employees in Regensburg and the subsidiary in
Toronto/Canada, reached break even in 2005 and is listed on the
German Stock Exchange, Frankfurt, since May 2006.